Skip to main content

Market Overview

BofA Downgrades DaVita On Low Exposure to Volume Rebound

BofA Downgrades DaVita On Low Exposure to Volume Rebound

Since dialysis is a stable business, Davita Inc (NYSE: DVA) remained resilient during the pandemic. However, now with acceleration in volumes is poised to begin, the company “is not as levered to the expected utilization rebound as peers,” according to BofA Securities.

The DaVita Analyst: Kevin Fischbeck downgraded the rating for DaVita from Neutral to Underperform, while reducing the price target from $127 to $118.

The DaVita Thesis: Hospitals are best positioned to benefit from the expected above average growth in procedures due to pent-up demand during the pandemic, Fischbeck said in the downgrade note.

“Health care utilization is likely to recover in the back half of 2021, with continued vaccinations and a return to elective procedures,” the analyst added.

Fischbeck noted, however, that DaVita is likely to underperform peers, with dialysis seeing “headwinds from high mortality.”

He elaborated in the note, “DVA guided to 2021 operating income (OI) slightly below expectations given same store volumes are expected to decline 1-2% y/y due to the higher mortality of dialysis patients during the pandemic.”

DVA Price Action: Shares of DaVita had declined by 2.43% to $108.17 at the time of publication Friday afternoon.

(Photo by JESHOOTS.COM on Unsplash)

Latest Ratings for DVA

Mar 2021B of A SecuritiesDowngradesNeutralUnderperform
Jan 2021B of A SecuritiesDowngradesBuyNeutral
May 2020SunTrust Robinson HumphreyMaintainsHold

View More Analyst Ratings for DVA
View the Latest Analyst Ratings


Related Articles (DVA)

View Comments and Join the Discussion!

Posted-In: BofA Securities Dialysis healthcare Kevin FischbeckAnalyst Color Downgrades Price Target Analyst Ratings

Latest Ratings

APENLake StreetInitiates Coverage On12.0
PATHMacquarieInitiates Coverage On69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at